Castle Biosciences (CSTL) Set to Post Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3480) per share and revenue of $92.77 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Castle Biosciences Stock Down 6.0%

Shares of NASDAQ:CSTL opened at $34.94 on Tuesday. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The company has a 50-day moving average price of $34.23 and a 200-day moving average price of $28.65. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CSTL shares. Mizuho assumed coverage on Castle Biosciences in a research note on Thursday, October 29th. They issued an “outperform” rating and a $60.00 target price on the stock. Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday. BTIG Research increased their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Insiders Place Their Bets

In other Castle Biosciences news, insider Tobin W. Juvenal sold 6,578 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $36.42, for a total transaction of $239,570.76. Following the transaction, the insider owned 38,853 shares in the company, valued at approximately $1,415,026.26. This represents a 14.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek Maetzold sold 8,580 shares of the stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $31.91, for a total value of $273,787.80. Following the completion of the transaction, the insider directly owned 12,484 shares of the company’s stock, valued at $398,364.44. This represents a 40.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 129,759 shares of company stock worth $4,434,187 over the last three months. Company insiders own 6.10% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.